InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study
SAN FRANCISCO – July 20, 2022 – InterVenn® Biosciences, a clinical technology company leveraging
glycoproteomics to transform the future of healthcare, today announced the start of enrollment in its prospective cohort study for early detection of colorectal cancer and adenomas. This confirmatory Noninvasive Identification of Colorectal Cancer and Adenomas in Early Stages – better known as the NICE Study – is intended to validate InterVenn’s platform to detect early colorectal cancers and precancerous adenomas with a high degree of accuracy from groundbreaking tiny quantities of blood. “InterVenn Biosciences was established with the mission that nobody should ever be blindsided by disease. Early detection is critical for fulfilling this promise to transform healthcare and significantly improve the patient experience,” said Tillman Pearce, Chief Medical Officer of InterVenn Biosciences. “The initiation of recruitment in our prospective NICE Study is a significant step forward for InterVenn as a pioneer to demonstrate that our platform has clinical utility to enable and accelerate detection of CRC at earlier stages than conventionally possible today with other methods.”
The NICE Study represents the next phase in InterVenn’s advancement toward improving cancer screening, building on the pilot data that the company presented at the ASCO healthcare conference in early June. The pilot data demonstrated positive results for the InterVenn platform for measuring glycosylation of circulating plasma proteins, detecting early CRC and precancerous advanced adenomas with high sensitivity from small amounts of peripheral blood.
– Dr. Misra, Gastroenterologist and EBGCR Research Director
As a multicenter, observational study the NICE Study is planned to enroll participants prior to a colonoscopy across major gastroenterology centers, such as Borland Groover, Blue Ridge Medical Center, East View Medical Research and Louisiana Research Center. This study, along with similar research that will be conducted, will support current and future discovery and clinical evidence for InterVenn’s early cancer product portfolio. InterVenn’s tests are developed on InterVenn’s perspectIV™ platform, which can directly interrogate the blood glycoproteome, for its own development or on behalf of partners.
InterVenn’s early cancer screening program includes a series of liquid biopsy-based assays that InterVenn develops to address a variety of cancers. InterVenn is building a robust pipeline of liquid biopsy tests to unlock the untapped, rich layer of biology called the glycoproteome, which is, in simpleterms, the entire set of sugars on proteins. Because of the essential roles glycoproteins play in physiological functions, the glycoproteome has the potential to be highly significant for real-time clinical decision-making.
Validation from the NICE Study will bring the power of InterVenn’s innovation to colorectal cancer screening, which can potentially help prevent and treat the disease in the future. The global market size for colorectal cancer screening, as reported by MarketWatch, is projected to reach almost $800 million by 2028 – up from almost $650 million in 2021. CRC is one of multiple types of cancers that InterVenn is tackling.
For more information about the NICE Study for CRC, please contact [email protected]
About InterVenn Biosciences
InterVenn is a clinical technology company unlocking the value of glycoproteomics for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to significantly improve patient outcomes, but it has remained inaccessible due to its vast complexity. InterVenn is pioneering a new AI-powered platform to decode and unlock the potential of the glycoproteome at clinically meaningful scale for the first time in history. To optimize this entirely new dimension of biology, the company has developed a platform capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.
***
Media Contact:
Anthony Petrucci
Bioscribe
[email protected]
512-581-5442